Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects
Curative surgical treatments, mainly liver resection, are still one of the optimal options for patients with early-, mid-, and even progression-stage hepatocellular carcinoma (HCC). However, the recurrence rate within 5 years after surgery is as high as 70%, especially in patients with high risk fac...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1098958/full |
| _version_ | 1797845550658224128 |
|---|---|
| author | Bin Guo Qian Chen Qian Chen Zhicheng Liu Xiaoping Chen Peng Zhu |
| author_facet | Bin Guo Qian Chen Qian Chen Zhicheng Liu Xiaoping Chen Peng Zhu |
| author_sort | Bin Guo |
| collection | DOAJ |
| description | Curative surgical treatments, mainly liver resection, are still one of the optimal options for patients with early-, mid-, and even progression-stage hepatocellular carcinoma (HCC). However, the recurrence rate within 5 years after surgery is as high as 70%, especially in patients with high risk factors for recurrence, most of whom experience early recurrence within 2 years. Effective adjuvant therapy may improve prognosis, previous studies found that adjuvant transarterial chemoembolization, antiviral, and traditional Chinese medicine et al. were helpful in preventing HCC recurrence. Nevertheless, due to controversial results or lack of high-level evidence, there is no standardized postoperative management protocol worldwide at present. Continued exploration of effective postoperative adjuvant treatments to improve surgical prognosis is necessary. |
| first_indexed | 2024-04-09T17:40:51Z |
| format | Article |
| id | doaj.art-9b0080192398416991d1dd0eb18ab9cc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T17:40:51Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9b0080192398416991d1dd0eb18ab9cc2023-04-17T05:44:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.10989581098958Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospectsBin Guo0Qian Chen1Qian Chen2Zhicheng Liu3Xiaoping Chen4Peng Zhu5Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaHepatobiliary Surgery Department, The First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaCurative surgical treatments, mainly liver resection, are still one of the optimal options for patients with early-, mid-, and even progression-stage hepatocellular carcinoma (HCC). However, the recurrence rate within 5 years after surgery is as high as 70%, especially in patients with high risk factors for recurrence, most of whom experience early recurrence within 2 years. Effective adjuvant therapy may improve prognosis, previous studies found that adjuvant transarterial chemoembolization, antiviral, and traditional Chinese medicine et al. were helpful in preventing HCC recurrence. Nevertheless, due to controversial results or lack of high-level evidence, there is no standardized postoperative management protocol worldwide at present. Continued exploration of effective postoperative adjuvant treatments to improve surgical prognosis is necessary.https://www.frontiersin.org/articles/10.3389/fonc.2023.1098958/fullhepatocellular carcinomacurative surgerytumor recurrencedisease-free survivaladjuvant therapy |
| spellingShingle | Bin Guo Qian Chen Qian Chen Zhicheng Liu Xiaoping Chen Peng Zhu Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects Frontiers in Oncology hepatocellular carcinoma curative surgery tumor recurrence disease-free survival adjuvant therapy |
| title | Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects |
| title_full | Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects |
| title_fullStr | Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects |
| title_full_unstemmed | Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects |
| title_short | Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects |
| title_sort | adjuvant therapy following curative treatments for hepatocellular carcinoma current dilemmas and prospects |
| topic | hepatocellular carcinoma curative surgery tumor recurrence disease-free survival adjuvant therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1098958/full |
| work_keys_str_mv | AT binguo adjuvanttherapyfollowingcurativetreatmentsforhepatocellularcarcinomacurrentdilemmasandprospects AT qianchen adjuvanttherapyfollowingcurativetreatmentsforhepatocellularcarcinomacurrentdilemmasandprospects AT qianchen adjuvanttherapyfollowingcurativetreatmentsforhepatocellularcarcinomacurrentdilemmasandprospects AT zhichengliu adjuvanttherapyfollowingcurativetreatmentsforhepatocellularcarcinomacurrentdilemmasandprospects AT xiaopingchen adjuvanttherapyfollowingcurativetreatmentsforhepatocellularcarcinomacurrentdilemmasandprospects AT pengzhu adjuvanttherapyfollowingcurativetreatmentsforhepatocellularcarcinomacurrentdilemmasandprospects |